Managing Excipient Supplier Name and Address Changes in the Pharmaceutical Quality System
Related Experiment Video
Updated: Dec 26, 2025

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Richard Rolke1, Emma Ramnarine2, Anders Vinther3
1Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Lansdale, PA, USA.
Abstract:
It is important to identify, assess, and address current barriers to implementation of post-approval changes that are intended to ensure continued (uninterrupted) operations and drive innovation and continual improvement in a maximally efficient, agile, and flexible pharmaceutical manufacturing sector. Leveraging the International Conference for Harmonisation Quality Guideline Q10 provides regulatory relief when it comes to addressing changes related to excipients, specifically excipient supplier's name and address changes, which will ensure a sustainable, reliable global supply and the availability of high quality product to patients through the entire commercial lifecycle of a product without extensive regulatory oversight.
More Related Videos
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
05:46Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drug Nomenclature
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Clinically Relevant Drug Product Specifications: Methods of Establishment